A Phase 1b Study of QX1206 in T2DM Patients With NAFLD

Summary

This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the recommended phase 2 dose. In addition, the preliminary effects of QX1206 on antidiabetic activity and other metabolic parameters will also be evaluated.

Timeline

Start

2025-01-06

Primary completion

2025-07

Completion

2025-12

Drugs

Indications